Literature DB >> 26271890

Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.

Majid Jaberi-Douraki1, Massimo Pietropaolo2, Anmar Khadra3.   

Abstract

Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of insulin-secreting pancreatic β cells, leading to abolition of insulin secretion and onset of diabetes. Cytotoxic CD4(+) and CD8(+) T cells, activated by antigen presenting cells (APCs), are both implicated in disease onset and progression. Regulatory T cells (Tregs), on the other hand, play a leading role in regulating immunological tolerance and resistant homoeostasis in T1D by suppressing effector T cells (Teffs). Recent data indicates that after activation, conventional Teffs transiently produce interleukin IL-2, a cytokine that acts as a growth factor for both Teffs and Tregs. Tregs suppress Teffs through IL-2 deprivation, competition and Teff conversion into inducible Tregs (iTregs). To investigate the interactions of these components during T1D progression, a mathematical model of T-cell dynamics is developed as a predictor of β-cell loss, with the underlying hypothesis that avidity of Teffs and Tregs, i.e., the binding affinity of T-cell receptors to peptide-major histocompatibility complexes on host cells, is continuum. The model is used to infer a set of criteria that determines susceptibility to T1D in high risk subjects. Our findings show that diabetes onset is guided by the absence of Treg-to-Teff dominance at specific high avidities, rather than over the whole range of avidity, and that the lack of overall dominance of Teffs-to-Tregs over time is the underlying cause of the "honeymoon period", the remission phase observed in some T1D patients. The model also suggests that competition between Teffs and Tregs is more effective than Teff-induction into iTregs in suppressing Teffs, and that a prolonged full width at half maximum of IL-2 release is a necessary condition for curbing disease onset. Finally, the model provides a rationale for observing rapid and slow progressors of T1D based on modest heterogeneity in the kinetic parameters.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Avidity-dependent dominance; Honeymoon period; Immunomodulation; Inter- and intra-clonal competition; Mathematical model

Mesh:

Year:  2015        PMID: 26271890      PMCID: PMC4567915          DOI: 10.1016/j.jtbi.2015.07.032

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  75 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors.

Authors:  Majedah Abdul-Rasoul; Hessa Habib; Maha Al-Khouly
Journal:  Pediatr Diabetes       Date:  2006-04       Impact factor: 4.866

3.  Induced regulatory T-cells (iTregs) generated by activation with anti-CD3/CD28 antibodies differ from those generated by the physiological-like activation with antigen/APC.

Authors:  Chan Zhao; Guangpu Shi; Barbara P Vistica; Samuel J H Hinshaw; Wambui S Wandu; Cuiyan Tan; Meifen Zhang; Igal Gery
Journal:  Cell Immunol       Date:  2014-06-27       Impact factor: 4.868

4.  Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells.

Authors:  Alessandra K Cardozo; Fernanda Ortis; Joachim Storling; Ying-Mei Feng; Joanne Rasschaert; Morten Tonnesen; Françoise Van Eylen; Thomas Mandrup-Poulsen; André Herchuelz; Décio L Eizirik
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

5.  Changes in autoreactive T cell avidity during type 1 diabetes development.

Authors:  Nathan E Standifer; Emily A Burwell; Vivian H Gersuk; Carla J Greenbaum; Gerald T Nepom
Journal:  Clin Immunol       Date:  2009-05-23       Impact factor: 3.969

6.  The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients.

Authors:  P Marchetti; M Bugliani; R Lupi; L Marselli; M Masini; U Boggi; F Filipponi; G C Weir; D L Eizirik; M Cnop
Journal:  Diabetologia       Date:  2007-09-30       Impact factor: 10.122

7.  A minimal model for T-cell vaccination.

Authors:  J A Borghans; R J De Boer
Journal:  Proc Biol Sci       Date:  1995-02-22       Impact factor: 5.349

Review 8.  Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention.

Authors:  Roland S Liblau; F Susan Wong; Lennart T Mars; Pere Santamaria
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

9.  Recovery of endogenous beta-cell function in nonhuman primates after chemical diabetes induction and islet transplantation.

Authors:  Rita Bottino; Angela Criscimanna; Anna Casu; Jing He; Dirk J Van der Windt; William A Rudert; Carla Giordano; Massimo Trucco
Journal:  Diabetes       Date:  2008-11-10       Impact factor: 9.461

10.  Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis.

Authors:  David Bending; Anne M Pesenacker; Simona Ursu; Qiong Wu; Hannah Lom; Balathas Thirugnanabalan; Lucy R Wedderburn
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

View more
  6 in total

Review 1.  miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.

Authors:  Ying Zheng; Zhen Wang; Zhiguang Zhou
Journal:  Cell Mol Immunol       Date:  2017-03-20       Impact factor: 11.530

2.  Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet β-cell Function in Severe Non-obese Diabetic Mice.

Authors:  Li-Rong Li; Xiao-Lei Jia; Hui Hui; Jie Zhang; Ying Liu; Wei-Juan Cui; Qian-Yue Xu; Da-Long Zhu
Journal:  Mol Med       Date:  2016-11-17       Impact factor: 6.354

3.  Quantifying immunoregulation by autoantigen-specific T-regulatory type 1 cells in mice with simultaneous hepatic and extra-hepatic autoimmune disorders.

Authors:  Hassan Jamaleddine; Pere Santamaria; Anmar Khadra
Journal:  Immunology       Date:  2020-09-11       Impact factor: 7.397

4.  Spatiotemporal Dynamics of Insulitis in Human Type 1 Diabetes.

Authors:  Kyle C A Wedgwood; Sarah J Richardson; Noel G Morgan; Krasimira Tsaneva-Atanasova
Journal:  Front Physiol       Date:  2016-12-27       Impact factor: 4.566

Review 5.  The Remission Phase in Type 1 Diabetes: Role of Hyperglycemia Rectification in Immune Modulation.

Authors:  Rong Tang; Ting Zhong; Chao Wu; Zhiguang Zhou; Xia Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-03       Impact factor: 5.555

6.  Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes.

Authors:  Laia Gomez-Muñoz; David Perna-Barrull; Josep M Caroz-Armayones; Marta Murillo; Silvia Rodriguez-Fernandez; Aina Valls; Federico Vazquez; Jacobo Perez; Raquel Corripio; Luis Castaño; Joan Bel; Marta Vives-Pi
Journal:  Front Immunol       Date:  2022-02-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.